Matrix metalloproteinases (MMPs) are involved in joint destruction in rheumatoid arthritis (RA), and are strongly associated with levels of inflammation. To understand the relationship between MMP-1 and -3 variants and MMP levels in RA, we investigated the genotypic and haplotypic relationships of the MMP-1 and -3 genes with circulating levels of these MMPs. The genotypes of single-nucleotide polymorphisms (SNPs) rs1799750 (1G/2G, MMP-1 promoter), rs495366 (G/A, intergene), rs679620 (A/G, MMP-3 coding region) and rs3025058 (5A/6A, MMP-3 promoter) were determined in 430 RA patients. Each polymorphism was associated with serum levels of MMP-1 (P trend o0.0001 for each SNP), with haplotype 1G-G-A-5A associated with the highest level. The intergenic and MMP-3 SNPs were associated with MMP-1 levels independent of the MMP-1 promoter SNP. The MMP-3 SNPs were associated with serum MMP-3 level (P trend o0.0001 for each SNP), and were each associated with mean time-averaged disease activity (DAS28) in patients followed up for 2 years (P ¼ 0.003). Our findings indicate that several closely linked polymorphisms in the MMP-1-MMP-3 loci have an important role in determining the circulating levels of these MMPs in RA, and that MMP-3 polymorphism is associated with the level of disease activity over time.
Introduction
Much of the joint damage in rheumatoid arthritis (RA) is believed to be mediated by abnormal release of matrix metalloproteinases (MMPs) in rheumatoid synovium stimulated by persistent inflammation. [1] [2] [3] [4] [5] MMPs are a group of zinc-and calcium-dependent proteases that contribute to tissue remodelling and repair during development, morphogenesis, inflammation, and so on. They act by specifically degrading all of the components of the extracellular matrix, which serves as a scaffold for tissue formation. In the synovial joint, MMPs are mainly secreted by fibroblasts, macrophages and chondrocytes.
There are at least 26 members of the MMP family in humans, classified into several subgroups according to the substrate specificity and structural similarities. MMP-1 (collagenase-1) and MMP-3 (stromelysin-1) are the most widely studied members in RA. MMP-1 is specifically responsible for degradation of type I collagen, a major component of the extracellular matrix, as well as other fibrillar collagens such as types II, III, V, IX and X. MMP-3 has a broader substrate specificity with activity against type II, III, IV, IX, X and XI collagens, proteoglycans, fibronectin and laminin. Furthermore, it is able to activate other MMPs such as MMP-1, -2, -9 and -13. Elevated levels of MMP-1 and -3 have been observed in patients with RA in both serum and synovial fluid, and are strongly associated with inflammation and joint destruction. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The genes for MMP-1 and -3 are both located on the long arm of chromosome 11, in a cluster together with seven other MMP members including MMP-7, -8, -10, -12 and -13. In recent years, functionally relevant and phenotype associated polymorphisms have been detected across the region of both genes. Several studies have examined the relationship between promoter polymorphisms in the MMP-1 (-1607 1G/2G) and MMP-3 (-1612 5A/6A) genes and the development and/or severity of RA. [20] [21] [22] [23] [24] [25] [26] [27] [28] No association has been found between these polymorphisms and susceptibility to RA, apart from one study that found a lower frequency of the MMP-3 5A allele in RA patients compared with controls. 28 Evidence of an association between these polymorphisms and disease severity has been found, although results between studies are conflicting.
A relationship between the MMP-3 5A/6A polymorphism and circulating levels of MMP-3 in RA has been found in two studies 23, 27 although another study found no relationship. 24 The latter study also found no relationship between the MMP-1 1G/2G polymorphism and circulating MMP-1 levels, but no other studies have investigated this.
Recent studies 29, 30 have highlighted the likely importance of other variations (rs495366 and rs679620) across the MMP-1 and -3 region in relation to MMP-1 levels 29 and MMP-3 function, 30 but these have not been investigated in patients with RA.
Serum levels of MMP-1, and MMP-3 in particular, have been considered to be a useful markers of inflammation in RA, 7, [9] [10] [11] [13] [14] [15] and have been shown to be predictive of joint destruction in early RA as well as reflecting ongoing joint damage in established RA. [11] [12] [13] 15 In this study, we provide the most detailed analysis to date of the genotypic and haplotypic relationships of the MMP-1 and -3 genes with circulating levels of these MMPs in RA, and have investigated whether polymorphisms at these loci are associated with the level of disease activity over time.
Results
Characteristics of the RA patients Table 1 displays the demographic and clinical characteristics of 430 subjects from a hospital-based population of RA patients.
Genotypic distribution, linkage disequilibrium and haplotypes
The frequencies of genotypes and alleles in the polymorphisms investigated are shown in the Table 2 . The w 2 goodness-of-fit test showed that the genotypic distributions of the four single-nucleotide polymorphisms (SNPs) were all in Hardy-Weinberg equilibrium.
Analysis with the Haploview program demonstrated that the MMP-3 SNPs rs3025058 and rs679620, and the intergenic SNP rs495366 were in the same linkage diseqilibrium (LD) block with D 0 being over 0.93 for all pairs (see Figure 1a ). Pairwise correlation (r 2 ) between rs3025058 and rs679620 was very high (0.98), whereas the correlation between rs495366 and the other 2 SNPs was only moderate (r 2 ¼ 0.38). A high D 0 and low r 2 can occur if the alleles that tend to occur on the same haplotype have very different allele frequencies. MMP-1 SNP rs1799750 was not included in this LD block. However, there was still a moderate LD between rs1799750 and the LD block, with D 0 ¼ 0.44 (see Figure 1b) , although the pairwise correlations between rs1799750 and the other SNPs were low (r 2 o0.2). According to the location of the SNPs, this LD block included at least part of the intergenic region of the MMP-1 and -3 genes, the whole MMP-3 gene and part of the MMP-3 promoter (Supplementary Figure S1 ).
It was noted that the majority of 1G alleles of rs1799750 (73%) were linked with the most frequent haplotype G-A-5A within the LD block (see Figure 1b) , thereby forming the 1G-G-A-5A haplotype, with a frequency of 38.3% (see Figure 1c) . Frequencies of other common haplotypes across the four SNPs are also listed (see Figure 1c) .
Association of MMP-1-MMP-3 loci with circulating levels of MMPs
The circulating levels of MMP-1 were determined on 413 subjects, while MMP-3 levels were measured in 411 patients. The relationships between MMP levels and parameters such as age, disease duration, sex, rheumatoid factor, antibodies to cyclic citrullinated peptides (anti-CCP), nodular disease and smoking were also investigated. Of these parameters, the only association found was an increased level of circulating MMP-3 in male patients (data not shown). This did not affect the main findings of the study.
The circulating levels of MMP-1 were not only associated with the MMP-1 promoter polymorphism rs1799750 but also with the markers of the LD block, including rs495366, rs679620 and rs3025058 (see Figures  2a-d) . In order to test whether the latter associations were independent from the former association, multivariate multiple regression analyses were carried out (adjusted for age, sex and disease duration) with rs1799750 and each of the other three SNPs as independent variables, and MMP-1 level (log transformed) as the dependent variable. In each model, both the association with rs1799750 and the LD block SNP remained significant, indicating the independence of these associations (see Table 3 , models 1, 2 and 3). There was also an association of the intergenic SNP (rs495366) independent of the MMP-3 SNPs (Table 3 , models 4 and 5). Number of subjects on which the genotype was determined.
Analysis of triple combinations of SNPs revealed a model in which rs1799750, rs495366 and rs3025058 were each independently associated with MMP-1 levels (Table 3 , model 6). In model 6, we show the rs3025058 SNP as being independent of rs1799750 and rs495366. However, replacement of rs3025058 with rs679620 in this model gives almost identical results. Analyses were also carried out which investigated possible interactions between SNPs by including a SNP Â SNP interaction term, as well as the main effects, in each analysis. None of the interaction terms were found to be significant.
Our data suggest that there is at least another functional site if not multiple sites, located probably within or close-by the LD block, which has functional effects on MMP-1 expression, apart from the rs1799750 polymorphism. The independent association of rs1799750 and rs3025058 with MMP-1 levels was confirmed in a second cohort of patients (n ¼ 291) with established RA (Supplementary Table S1 ).
In un-adjusted analyses of single SNPs, the circulating levels of MMP-3 were associated with the MMP-3 SNPs rs679620 and rs3025058, but not with the MMP-1 SNP rs1799750 or the intergenic SNP rs495366 (see Figures 2e-h ). The G allele of rs679620 and the 6A allele of rs3025058 were associated with the highest levels of circulating MMP-3. Interestingly, in joint analysis of two SNP combinations (adjusted for age, sex and disease duration) we found that the MMP-1 SNP rs1799750 was associated with MMP-3 levels after adjustment for the intergenic SNP (Table 3 , model 1). However, the MMP-1 SNP was no longer associated when analyzed jointly with either of the MMP-3 SNPs (Table 3 , models 2 and 3). In contrast, the intergenic SNP demonstrated an association with MMP-3 levels (GG4AG4AA, Pp0.01) when adjusted for either MMP-3 SNP, each of which remained highly significant (Po0.0001) ( Table 3 , models 4 and 5). The association of rs3025058 with MMP-3 levels was confirmed in a second cohort of patients (Supplementary  Table S1 ).
We next tested the haplotypic associations with MMP-1 and MMP-3 levels (Table 4) . Analysis with the HAPSTAT program indicated that the 1G-G-A-5A haplotype (rs1799750, rs495366, rs679620 and rs3025058) was associated with the highest levels of MMP-1 (Po0.0001, in both additive and dominant models, vs the remaining haplotypes). This association could be explained mainly by the two SNP 1G-5A haplotype because over 98% of patients with this haplotype carried 1G-G-A-5A. The 2G-A-G-6A haplotype was correlated with the lowest levels of MMP-1 (Po0.0001, in both additive and dominant models, vs the remaining haplotypes). Furthermore, the 1G-A-G-6A haplotype was also associated with low MMP-1 levels compared with the other haplotypes, excluding 2G-A-G-6A (Pp0.02 in both additive and dominant models). This supports the idea that the polymorphisms within the LD block region have a strong effect on the regulation of MMP-1 expression, independent of the rs1799750 polymorphism.
The four SNP haplotype associated with the highest MMP-3 levels was 2G-G-G-6A (P ¼ 0.004 and P ¼ 0.003 in additive and dominant models, respectively, vs the remaining haplotypes), although the association was stronger after exclusion of the rs1799750 SNP (G-G-6A, Po0.0001). Owing to the high LD and correlation between rs679620 and rs3025058, the association could be explained mainly by the two SNP (rs495366-rs679620) G-G haplotype or the (rs495366-rs3025058) G-6A haplotype, both of which gave highly significant associations (Po0.0001). This association was lost if the rs495366 G allele was replaced by the A allele to give A-G or A-6A haplotypes (P40.5). The lowest MMP-3 levels were associated with the 1G-G-A-5A haplotype, although this could be explained mainly by the two SNP haplotype G-5A (rs495366-rs3025058). Association of the MMP-1-MMP-3 loci with disease activity Previous studies have shown significant correlations of MMP-1, and particularly MMP-3 serum levels with levels of inflammation in RA. 7, [9] [10] [11] [13] [14] [15] In this study, we found significant correlations of MMP-1 and MMP-3 with the level of disease activity (DAS28 at baseline Figure 2 Relationship between MMP genotypes and circulating levels of MMPs. Panels (a-d) show serum levels of MMP-1 in patients with different genotypes of rs1799750, rs495366, rs679620 and rs3025058, respectively. Panels (e-h) show serum levels of MMP-3 in patients with genotypes of rs1799750, rs495366, rs679620 and rs3025058, respectively. Horizontal bars represent the median (long bars) and interquartile ranges (short bars).
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Y Chen et al We therefore investigated whether there was a relationship between variations across the MMP-1-MMP-3 loci and the DAS28. DAS28 scores can fluctuate over time, so we chose to look at the association with the mean timeaveraged DAS28 in 304 patients followed up over a 2-year period (DAS28 at baseline, 12 and 24 months). We believed that this would be more representative of the longer term level of disease activity in each patient than DAS28 measured at a single time point.
In separate multivariate analyses we found that MMP-3 SNPs rs3025058 or rs679620 were associated with the mean time-averaged DAS28 over 2 years (P ¼ 0.003). There was an increasing time-averaged DAS28 with increasing rs3025058 5A allele dose or rs679620 A allele dose. These associations were independent of age, sex, disease duration, baseline MMP-1 and MMP-3 levels, presence of rheumatoid factor or anti-CCP, nodular disease, erosive disease, baseline health assessment questionnaire, ever having smoked and type of therapy (DMARD, steroid, biologic). The best multivariate model predictive of a higher level of DAS28 over 2 years consisted of baseline health assessment questionnaire, baseline MMP-3 level, presence of anti-CCP and increasing rs3025058 5A allele dose (Table 5) . Baseline MMP-1 level was not associated in this model.
Analysis of haplotypes revealed a significant association of the G-A (rs495366-rs679620) haplotype with mean time-averaged DAS28 in an additive model (P ¼ 0.04). The association with the G-5A haplotype (rs495366-rs3025058) did not reach significance, but showed a similar trend (P ¼ 0.07).
Discussion
In this study, we have demonstrated a relationship between important polymorphisms across the MMP-1 and -3 genetic loci and the circulating levels of MMP-1 and -3 in patients with RA. We have also shown that polymorphism in the MMP-3 locus is associated with the mean time-averaged level of disease activity (DAS28) over a 2-year period.
To our knowledge, we are the first group to have demonstrated an association of the rs1799750 polymorphism with serum levels of MMP-1 in patients with RA. rs1799750 is a deletion-insertion polymorphism where an additional guanine (G) creates an E26 transformation specific-1 (Ets) binding site at À1607 bp in the MMP-1 promoter. The resulting 2G allele has been shown to be associated with higher transcriptional activity in normal fibroblasts and in melanoma in vitro. 32 However, in this study it was the 1G allele, rather than the 2G, that was associated with higher MMP-1 serum levels. As we also found that the 1G allele of rs1799750 and the G allele of rs495366 were in linkage disequilibrium our findings are consistent with the observation of Cheng et al. 29 who showed that the G allele of rs495366 is associated with higher serum levels of MMP-1 in healthy subjects.
We confirmed the association of the intergenic rs495366 SNP with MMP-1 levels and have shown for the first time that MMP-3 SNPs rs679620 and rs3025058, located in the same LD block, are also associated with MMP-1 levels, independent of the rs1799750 association. The G allele of rs495366 has been suggested to be the strongest marker associated with high MMP-1 levels in a genome-wide association study. 29 It is interesting that the rs495366 G allele is associated with either higher MMP-1 or higher MMP-3 levels, depending on which MMP-1-MMP-3 haplotype it is linked with. This suggests that this region has an important effect on modulating both MMP-1 and MMP-3 levels.
Although rs679620 and rs3025058 are functional polymorphisms in the MMP-3 gene and any change of MMP-3 expression/activity may potentially influence MMP-1 release, there is currently no direct evidence to support such a relationship. The LD block identified in this study may extend to the promoter region of the MMP-1 gene where there may be other polymorphisms, which alter transcriptional activity.
Polymorphism rs679620, located in exon 2 of the MMP-3 gene, results in an amino acid change (Glu4Lys) at residue 45. On the basis of the Hapmap August 2010 phaseII þ III database, this SNP is the only common SNP across the coding region of the MMP-3 gene, which leads to an amino acid alteration in the CEU population (Utah residents with Northern and Western European ancestry). Residue 45 is located just after the first alpha helix in the propeptide, in a region that is believed to be flexible. It has been suggested that the amino acid change at this residue could potentially alter its interaction with other amino acids in this region, and have an effect on MMP-3 activation. However, the Glu45 residue is not conserved across species, suggesting that the Lys45Glu polymorphism is unlikely to have a significant functional impact. 30 According to our data and the data reported by Beyzade et al., 30 the genotypic/allelic distributions of rs679620 and rs3025058 were almost identical, so either SNP could be used as a marker for the association with MMP-3 levels.
The MMP-3 promoter polymorphism rs3025058 has been reported to influence the transcriptional activity of MMP-3, with the 5A allele being associated with higher transcriptional activity. 33, 34 However, in contrast, the results of studies on patients with RA, in the current and two other studies, 23, 27 have consistently shown that the 6A allele is associated with higher serum levels of MMP-3. Similar contradictory results have also been shown in studies on patients with coronary heart disease and/or myocardial infarction. [35] [36] [37] The reason for this discrepancy is still unclear, although in the case of .
MMP polymorphism in RA Y Chen et al myocardial infarction patients it has been postulated that increased activation of pro-MMP-3 within the atherosclerotic vessel wall may potentially lead to decreased leakage of pro-MMP-3 and/or inactivated MMP-3 into the blood stream. 35 A similar argument could be put for the inflamed synovial joint.
Serum levels of MMP-3 have been suggested to mainly reflect levels of inflammation in RA. Our data further indicate that polymorphism in the MMP-3 gene is associated with the level of disease activity over time, and that this is independent of other factors associated with higher levels of disease activity, including high serum levels of MMP-3, poor function and the presence of anti-CCP. Interestingly, the highest level of disease activity appears to be associated with the rs3025058 5A allele (or the rs679620 A allele), which is associated with lower circulating levels of MMP-3 (although it is also associated with the highest levels of MMP-1). However, this genetic association appears to be independent of serum levels of MMP-1 and MMP-3. The association of the MMP-3 polymorphism with disease activity is therefore not a straightforward reflection of circulating MMP levels, but may somehow reflect the expression and local activity of individual MMPs within the joint. This may depend on the conditions within the joint. Recent work has suggested that the 5A/6A polymorphism is functional only during specific environmental conditions involving inflammation. 34 It has also been shown that the transcription factor NFkappaB has differential effects on 5A and 6A alleles in macrophages, with the greater transcriptional activity of 5A being augmented by NFkappaB activation. 38 Differential expression of MMP-1 in response to inflammatory mediators has also been linked to the MMP-1 1G/2G promoter polymorphism, 39, 40 although one study found that strong and repeated inflammatory stimulation of macrophages resulted in higher MMP-1 expression irrespective of MMP-1 1G/2G genotype. 41 The possibility of cell-and tissuespecific differences in gene expression cannot be ruled out. Further work is therefore needed to investigate the influence of MMP-1 and -3 polymorphisms on the expression of MMP-1 and -3 in different cell types of the joint and circulation, and whether this is different under normal and inflammatory conditions.
In conclusion, this study provides further insight into the relationship between the MMP-1-MMP-3 loci and MMP-1-MMP-3 levels, and indicates that several closely linked polymorphisms in the MMP-1-MMP-3 loci have an important role in determining the circulating levels of these MMPs in RA. Polymorphism within the MMP-3 gene may also influence the overall level of disease activity in RA. Future studies are needed to determine the relationship between MMP-1 and -3 genetic variants and the expression levels of these MMPs in the tissues of the joint, and how this relates to circulating protein levels and disease activity. In addition, further functional characterization of the possible causative MMP-1 and -3 variants associated with clinical phenotypes will be needed to determine the relevance of genetic variation at these loci to the pathogenesis of RA.
Materials and methods

Patients
We studied a cohort (n ¼ 430) of consecutively recruited RA patients of Caucasian origin, resident in North Staffordshire, England. All patients satisfied the 1987 ACR diagnostic criteria for RA. 31 A majority (93%) of the patients were being treated with one or more diseasemodifying anti-rheumatic drugs including methotrexate, sulphasalazine or hydroxychloroquine. A number of the patients were on biologic agents (mainly etanercept and infliximab) at the time of recruitment (14%). For replication studies, archival samples of DNA and serum were available from a second cohort of patients (n ¼ 291) with established RA who had been used in previous studies of MMP-3 and disease outcome in RA. 11, 23 Ethical approval was obtained from the North Staffordshire local research ethics committee and written informed consent was provided by all patients.
A core set of clinical variables was recorded at recruitment. This included the disease activity score (DAS28), 42 disability index of the health assessment questionnaire, 43 C-reactive protein, erythrocyte sedimentation rate, IgM rheumatoid factor, anti-CCP and presence of rheumatoid nodules. Demographic information and history of current or past cigarette smoking were given by each patient. Patients considered as smokers were those who had smoked at least 1 cigarette per day for at least 1 year. Peripheral blood samples were collected for DNA isolation or serum separation.
Genotyping
Genomic DNA was isolated from peripheral blood leukocytes using a Nucleon DNA extraction kit (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instructions. PCR-restriction fragment length polymorphism analysis was applied to determine the genotype of the rs1799750, rs495366, rs679620 and rs3025058 polymorphisms. The genotyping methods for SNPs rs1799750, rs679620 and rs3025058 were described previously in (refs 44-46) , respectively.
The rs495366 polymorphism was identified using the following primers: forward: 5 0 -TGAGCTCCCGAAAGGT AGAA-3 0 and reverse: 5 0 -TGAGACCACATCAGTCTTG TGA-3 0 . PCR was performed in a 20 ml volume made up of 2 ml (20 ng) of diluted genomic DNA, 2 ml of 10 Â reaction buffer, 1.2 ml of 50 mM MgCl 2 (Invitrogen, Paisley UK) , 3 ml of 2 Â poly-mate additive (Bioline, London, UK), 1.6 ml of 2 mM dNTP mix (Invitrogen, Paisley, UK), 1 ml of each 10 mM primer, 0.2 ml of 5 U ml -1 Taq polymerase (Invitrogen) and 8 ml of dH 2 O. The PCR cycling conditions were 4 min at 94 1C followed by 35 cycles of 30 s at 94 1C, 30 s at 58 1C and 1 min at 72 1C, with a final extension step at 72 1C for 5 min. All amplification reactions were performed in a Flexigene thermal cycler (Techne Limited, Cambridge, UK) using a 96-well heating block. There was a recognition site (5 0 yC/ TRYAGy3 0 ) for the restriction enzyme SfcI (New England BioLabs, Beverly, MA, USA) in the case of the G allele. In all, 10 ml of PCR product was digested with two units of SfcI overnight at 25 1C, and the digest product was separated by electrophoresis on 4% agarose gels stained with ethidium bromide. The A allele exhibited an undigested 169-bp band, whereas the G allele displayed 79-bp and 90-bp bands.
Quantification of circulating levels of MMP-1 and -3 Measurement of circulating MMP-1 and -3 was performed on the serum samples using Fluorokine MAP multiplex kits (R&D Systems, Minneapolis, MN, USA) and was read on a Luminex suspension array system (Bio-Plex 200, Bio-Rad, Hemel Hempstead, Hertfordshire, UK). Sample preparation and assay procedure were followed according to the manufacturer's recommendation. In all, 3 mg ml -1 of Heteroblock (Omega Biologicals, Bozeman, MT, USA) was added into the sample diluent before assay to block any nonspecific binding to rheumatoid factor. 47 
Statistical analysis
Using Haploview (version 4.2), 48 Hardy-Weinberg equilibrium for the genotypic distributions of each polymorphism was tested with the w 2 goodness-of-fit test. LD index, D 0 , 49 was used to estimate the strength of LD between each pair of markers. The LD block was defined by the four gamete rule. The haplotype frequencies were estimated using an expectation-maximization algorithm to determine the maximum-likelihood frequencies of multi-locus haplotypes.
50 Figure 1 was exported from the Haploview program. P-values for trend were determined by Jonckheere Terpstra test (non-parametric distributed quantitative trait) or by extended Mantel-Haenszel test (binary trait) using WinPEPI (version 9.4, free software by JH Abramason, www.brixtonhealth.com). Figure 2 was produced in Graphpad (version 5.0, Graphpad Software Inc, La Jolla, CA, USA). The relationship between haplotypes and MMP levels was analyzed under regression-based models in HAPSTAT (version 3.0, Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA). 51 MMP levels were transformed to normality using log transformation. Multivariate logistic or linear regression analyses were also carried out using Number Cruncher Statistical System for Windows (NCSS 2000, NCSS Statistical Software, Kaysville, UT, USA) to test the independence of associations and to adjust for potential confounding factors. The significance level was set at a P-value of 0.05. All P-values were based on two-tailed tests.
